EcoDrugPlus

Dna Topoisomerase 2-Beta-Like

Ensembl ID : ENSOKIG00005017507
Gene Symbol: LOC109907375
3 Cross references
201 Possible Orthologues:

Dna Topoisomerase 2-Beta-Like

Ensembl ID : ENSOKIG00005004912
Gene Symbol: LOC109904415
3 Cross references
201 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSOKIG00005024944
Gene Symbol: TOP1
3 Cross references
198 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSOKIG00005014247
Gene Symbol: TOP2A
1 Cross references
209 Possible Orthologues:

E3 Ubiquitin-Protein Ligase Mdm2-Like

Ensembl ID : ENSOKIG00005021957
Gene Symbol: LOC109885926
3 Cross references
281 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSOKIG00005000244
Gene Symbol: EML4
3 Cross references
195 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSOKIG00005003765
Gene Symbol: EML4
3 Cross references
196 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSOKIG00005020532
Gene Symbol: EPHA3
3 Cross references
206 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSOKIG00005000835
Gene Symbol: EPHA3
1 Cross references
206 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSOKIG00005005704
Gene Symbol: F2RL3
3 Cross references
189 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSOKIG00005042060
Gene Symbol: F2RL3
3 Cross references
189 Possible Orthologues:

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion

Ensembl ID : ENSOKIG00005033354
Gene Symbol: FAU
1 Cross references
294 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).